How to Enter Clinical Trials For Cancer Treatments

How to Enter Clinical Trials

Endostatin was the first endogenous angiogenesis inhibitor to enter into clinical trials. Endostatin given to 21 advanced solid tumor patients daily as a 1-hour intravenous infusion (for 28 days) was well - tolerated (Thomas et al 2003).

The safety and efficacy of recombinant human Angiostatin protein administered in combination with chemotherapy (paclitaxel and carboplatin) to patients with non-small-cell lung cancer is currently being investigated in a clinical trial: http://clinicaltrials.gov/ct/search?term=angiostatin

For more information about cancer clinical trials call the Cancer Information Service, (800) 4-CANCER.

Physicians may request information about trials from the PDQ Search Service by calling (800) 345-3300, faxing (800) 380-1575, or e-mailing pdqsearch@icicc.nci.nih.gov.

There are many anti - angiogenesis drugs in clinical studies. In some cases, the FDA may allow an unapproved drug to be released before it is officially approved. Here are some of the anti - angiogenesis drugs being tested and the sponsoring companies: